Nasdaq:SRTA
Strata Critical Medical, Inc.
A specialized manufacturer of sterile critical care medical supplies focusing on high-demand items for US hospitals and urgent care centers.
Key Metrics
Investment Thesis
Bull Case
Investors may see value in SRTA due to its robust top-line growth trajectory driven by post-pandemic demand for critical care supplies and potential market share gains from competitors exiting the space. The company's substantial paid-in capital base provides a buffer against current losses, while its specialized product line offers high barriers to entry that could support future margin expansion.
Bear Case
The persistent double-digit net losses and a massive retained earnings deficit of -$186.9M raise concerns about the sustainability of current growth without significant operational turnaround. With cash reserves declining from $29.0M to $18.4M and heavy capital spending, the company risks liquidity issues if it cannot achieve profitability soon.
About Strata Critical Medical, Inc.
Strata Critical Medical, Inc. (SRTA) is a leading provider of critical care medical supplies, specializing in sterile, single-use products for emergency departments and intensive care units. The company primarily serves the United States market with a diverse portfolio including ventilator systems, airway management devices, and fluid therapy solutions designed to support acute patient care needs.
Analysis
Management Discussion
Despite a strong 72% revenue increase from 2022 to 2024, the company recorded net losses of $27.3M in both 2023 and 2024, with operating profit declining to -$33.9M due to rising cost of revenue and general administrative expenses. Cash flow from operations turned negative at -$2.5M, partially offset by significant non-cash adjustments including share-based compensation and depreciation totaling $38.5M.
Industry Overview
The critical care medical supplies industry is characterized by high regulatory standards and a demand for reliable, sterile products essential for hospital operations. Consolidation among competitors and supply chain disruptions have created opportunities for agile players like SRTA to capture market share in the United States healthcare sector.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $146.1M | $225.2M | $248.7M |
| Cost of Revenue | $123.8M | $183.1M | $189.8M |
| Gross Profit | $22.3M | $42.1M | $58.9M |
| Operating Expenses | $-36.6M | $-33.2M | $92.8M |
| Operating Income | $-53.5M | $-68.1M | $-33.9M |
| G&A | $62.5M | $95.2M | $81.7M |
| Marketing | $7.7M | $10.4M | $8.0M |
| Stock-Based Comp | $8.3M | $12.5M | $19.9M |
| D&A | $5.7M | $7.1M | $6.0M |
| Depreciation | $830.0K | $1.1M | $3.0M |
| Amortization | $4.9M | $6.0M | $3.0M |
| Other OpEx | $-106.8M | $-138.8M | $3.2M |
| Non-Operating Income | $25.5M | $10.6M | $6.4M |
| Pre-Tax Income | $-28.0M | $-57.5M | $-27.6M |
| Income Tax | $-772.0K | $-1.5M | $-255.0K |
| Continuing Ops | $-27.3M | $-56.1M | $-27.3M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-27.3M | $-56.1M | $-27.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-27.3M | $-56.1M | $-27.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $218.1M | $206.3M | $160.7M |
| Cash & Equivalents | $43.3M | $27.9M | $18.4M |
| Accounts Receivable | $10.9M | $21.0M | $21.6M |
| Prepaid Expenses | $12.1M | $18.0M | $10.7M |
| Other Current Assets | $151.9M | $139.4M | $110.0M |
| Long-Term Assets | $106.9M | $88.7M | $95.9M |
| PP&E (Net) | $2.0M | $2.9M | $30.9M |
| Intangibles | $46.4M | $20.5M | $13.7M |
| Goodwill | $39.4M | $40.4M | $41.0M |
| Operating Leases | $17.7M | $23.5M | $8.9M |
| Other LT Assets | $1.4M | $1.4M | $1.4M |
| Total Assets | $325.0M | $294.9M | $256.7M |
| Current Liabilities | $26.6M | $35.5M | $22.7M |
| Current Leases | $3.4M | $4.8M | $3.3M |
| Deferred Revenue | $6.7M | $6.8M | $6.7M |
| Other Current Liab | $16.5M | $23.9M | $12.8M |
| Long-Term Liabilities | $23.9M | $25.1M | $12.0M |
| LT Operating Leases | $15.0M | $19.7M | $6.0M |
| Other LT Liab | $9.0M | $5.4M | $6.0M |
| Total Liabilities | $50.5M | $60.6M | $34.7M |
| Shareholders' Equity | $274.5M | $234.3M | $221.9M |
| Paid-In Capital | $375.9M | $390.1M | $407.1M |
| Retained Earnings | $-103.7M | $-159.8M | $-186.9M |
| AOCI | $2.3M | $4.0M | $1.8M |
| Total L&E | $325.0M | $294.9M | $256.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-27.3M | $-56.1M | $-27.3M |
| Non-Cash Adjustments | $-31.8M | $-1.7M | $38.5M |
| Working Capital Changes | $21.9M | $25.4M | $-13.7M |
| Cash from Operations | $-37.1M | $-32.3M | $-2.5M |
| Capital Expenditures | $730.0K | $2.1M | $30.9M |
| Cash from Investing | $79.3M | $17.1M | $-1.0M |
| Share Buybacks | — | — | $244.0K |
| Cash from Financing | $-1.1M | $-76.0K | $-5.8M |
| FX Effect | $72.0K | $-66.0K | $-80.0K |
| Net Change in Cash | $41.2M | $-15.4M | $-9.4M |
| Beginning Cash | $3.2M | $44.4M | $29.0M |
| Ending Cash | $44.4M | $29.0M | $19.6M |
Frequently Asked Questions
How does Strata Critical Medical, Inc. make money?
The company's revenue is driven by its core segments in Airway Management, which includes ventilators and intubation tools; Fluid Therapy, covering IV bags and tubing; and Respiratory Care, encompassing various breathing support devices. Additional growth comes from sterile consumables sold directly to healthcare facilities and through strategic distribution networks.
What are the main risks for SRTA?
Significant ongoing net losses and an expanding retained earnings deficit indicate persistent profitability challenges despite revenue growth. Heavy capital expenditures suggest potential cash flow strain if operational efficiency does not improve soon. The company faces exposure to foreign exchange fluctuations impacting its bottom line and reliance on a concentrated geographic market for critical care supplies.
What is SRTA's competitive advantage?
SRTA leverages a proprietary manufacturing process that ensures high-quality sterile products while maintaining competitive pricing margins. The company benefits from established relationships with major hospital systems and a product portfolio that is difficult for new entrants to replicate quickly due to regulatory hurdles and supply chain complexity.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.